Systemic lupus erythematosus
Not yet recruitingComparing certolizumab pegol and belimumab for patients with moderate or severe systemic lupus erythematosus
Comparing certolizumab pegol and belimumab for patients with moderate or severe systemic lupus erythematosus
- Disease:Systemic lupus erythematosus
- Substances:BelimumabCertolizumab Pegol
Poland- Participants:18–64 years · 65+ years
- Substances:Belimumab
- Sponsor:Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory Reicher
